Core Points - BeiGene (06160) announced that on September 30, 2025, the Board's Compensation Committee granted a total of 36,000 restricted stock units involving American Depositary Shares to 237 grantees under the 2016 Option and Incentive Plan [1] - Additionally, one grantee was awarded 2,935 performance stock units involving American Depositary Shares [1]

Core Viewpoint - BeiGene (06160.HK) announced the grant of restricted stock units and performance stock units to 237 recipients, totaling 36,000 American Depositary Shares (ADS) [1] Summary by Categories - **Stock Grants** - The board's compensation committee granted a total of 36,000 restricted stock units to 237 recipients [1] - Additionally, one recipient was awarded 2,935 performance stock units [1] - **Equity Impact** - The restricted stock units and performance stock units correspond to 509,197 shares, which represents approximately 0.03% of the company's total issued shares as of the announcement date [1]

Core Viewpoint - BeiGene (06160) announced the grant of restricted stock units and performance stock units to its employees as part of its 2016 option and incentive plan, indicating ongoing commitment to employee incentives and retention [1] Summary by Categories Company Actions - The board's compensation committee granted a total of 36,000 American Depositary Shares (ADS) in restricted stock units to 237 grantees [1] - Additionally, one grantee received 2,935 ADS in performance stock units [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 百濟神州有限公司 (根據瑞士法律註冊成立的公司) 呈交日期: 2025年10月8日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06160 | 說明 | 請見備注 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 2,311,463,847 | USD | | 0.0001 USD | | 231,146.38 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 2,311,463,847 | USD | | 0.0001 USD | | 231,146.38 | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeOne Medicines Ltd. 百濟神州有限公司 （根據瑞士法律註冊成立的公司） （股份代號：06160） 授出受限制股份單位及業績股份單位 本公告乃根據上市規則第17.06A、17.06B以及17.06C條作出。於2025年9月30 日，董事會薪酬委員會根據2016期權及激勵計劃的條款向二百三十七名承授人授 出涉及合共36,234股美國存託股份的受限制股份單位，並向一名承授人授出涉及 合共2,935股美國存託股份的業績股份單位。 2016期權及激勵計劃項下的受限制股份單位及業績股份單位 於2025年9月30日，董事會薪酬委員會根據2016期權及激勵計劃的條款授予二百 三十七名承授人合共36,234股美國存託股份受限制股份單位，並向一名承授人授 出合共2,935股美國存託股份業績股份單位。該等受限制股份單位及業績股份單位 相當於509,197股股份，約佔本公告之日公司發行股份總數的0.03%。 ...

Core Viewpoint - Pharmacyclics LLC has decided not to appeal the final written decision from the USPTO regarding the patent dispute with BeiGene, leading to the voluntary withdrawal of the lawsuit by both parties [1][4]. Group 1: Legal Proceedings - On June 13, 2023, Pharmacyclics filed a lawsuit against BeiGene and its subsidiary BeOne Medicines USA, claiming that the product Brukinsa infringed on its US patent No. 11,672,803 [4]. - The court agreed to suspend the infringement lawsuit pending the outcome of BeiGene's application for a post-grant review (PGR) of the '803 patent, which is due by November 1, 2023 [4]. - On April 29, 2025, the USPTO declared the '803 patent invalid, and Pharmacyclics had the option to appeal this decision [4][5]. Group 2: Financial Performance - In the first half of 2025, BeiGene reported total revenue of 17.518 billion yuan, a year-on-year increase of 46.0%, and achieved a net profit of 450 million yuan, compared to a loss of 2.877 billion yuan in the same period last year [7]. - The majority of BeiGene's revenue came from international markets, with overseas sales of Brukinsa reaching 11.335 billion yuan, accounting for 65.3% of total revenue, while sales in China were 1.192 billion yuan [7]. Group 3: Historical Financials - From 2017 to 2020, BeiGene experienced significant net losses, with figures of 982 million yuan, 4.747 billion yuan, 6.915 billion yuan, and 11.384 billion yuan respectively [5]. - The company continued to incur losses from 2021 to 2023, with net losses of 9.748 billion yuan, 13.642 billion yuan, and 6.716 billion yuan [5].

Core Insights - The Global X China Biotechnology ETF (02820) recorded positive returns in August, driven by globalization themes, domestic policy support, improved corporate earnings, and a favorable macro environment [1] - Significant foreign licensing transactions highlight global recognition of the innovation quality of Chinese companies, with an accelerating trend in the number and upfront payment amounts for such transactions over the past two years [1] - The Chinese biotechnology sector is expected to continue being a strong performer in 2023, with improved investor sentiment towards the healthcare sector due to enhanced earnings and commercialization processes [1] Industry Summary - The Chinese biopharmaceutical industry is being propelled by high-quality technology empowerment and policy support, as emphasized by the Chinese Premier during a recent visit [1] - The National Healthcare Security Administration has released a final list of drugs eligible for negotiation, with domestic biotech companies optimistic about upcoming negotiations becoming more favorable and flexible [1] - Reports indicate that the U.S. government is drafting an executive order to restrict Chinese pharmaceuticals and innovative therapies, but Chinese biotech firms may demonstrate resilience due to their capabilities in conducting global clinical trials [2] Company Analysis - Jiangsu Hengrui Medicine (01276) reported Q2 2025 revenue of 8.6 billion RMB (up 12.5% YoY) and a net profit of 2.6 billion RMB (up 25% YoY), with significant contributions from recent IPOs and licensing agreements [3] - Hengrui's new revenue growth point comes from collaboration income, including a licensing agreement with Merck that generated approximately 1.5 billion RMB [3] - Hengrui's recent licensing agreement with Braveheart Bio includes a $65 million upfront payment and potential milestone payments, indicating a strong pipeline for future licensing income [3] - BeiGene (06160) reported Q2 2025 revenue of $1.3 billion (up 18% QoQ) and a net profit of $94.3 million, exceeding market expectations, driven by strong sales of its product BRUKINSA [4] - BeiGene announced a deal with Royalty Pharma to sell sales-sharing rights for its anti-tumor drug IMDELLTRA outside China for up to $950 million, enhancing its cash reserves for future opportunities [4] - The Global X China Biotechnology ETF (02820) invests in 30 companies primarily engaged in the research, development, manufacturing, and distribution of biopharmaceuticals [4]

A 股代码：688235 A 股简称：百济神州 公告编号：2025-036 港股代码：06160 港股简称：百济神州 美股代码：ONC 百济神州有限公司 关于公司涉及诉讼的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、本次诉讼的基本情况及最新进展 2023 年 6 月 13 日，Pharmacyclics LLC 公司（作为申诉方，以下简称 "Pharmacyclics"）在美国特拉华州地方法院对百济神州有限公司（以下简称 "公司"）及公司全资子公司 BeOne Medicines USA, Inc（. 前称 BeiGene USA, Inc.） （作为被申诉方）提出申诉，声称公司产品百悦泽®侵犯了其于 2023 年 6 月 13 日授权的美国专利编号为 11,672,803 的专利（以下简称"'803 专利"），并请 1 案件所处的诉讼阶段：双方已向法院提交一份共同协议，自愿撤回案件， 案件已做出终局处理。 公司所处的当事人地位：本次诉讼的被申诉方。 是否会对公司损益产生负面影响：本次诉讼 ...

Market Overview - The Hang Seng Index (HSI) closed at 26,857.70, down by 100.07 points or 0.37% as of October 7, 16:00 Eastern Time [1] - The index reached a high of 27,169.45 and a low of 26,849.11 during the trading session, with a trading volume of 47.63 million [1] - The HSI's 52-week high is 27,275.90 and the low is 18,856.77, indicating a trading range of 1.19% [1] Blue-Chip Stocks Performance - Major blue-chip stocks mostly declined, with HSBC Holdings closing at HKD 110.069, down 0.75% from the Hong Kong market close [2] - Tencent Holdings closed at HKD 670.363, down 1.05% compared to the Hong Kong market close [2] Individual Stock Movements - Tencent Holdings (00700) saw a slight increase of 0.59% to HKD 677.500, but its ADR price was HKD 670.363, reflecting a decrease of 7.137 [3] - Alibaba Group (09988) decreased by 2.49% to HKD 180.500, with its ADR price at HKD 176.415, down by 4.085 [3] - HSBC Holdings (00005) increased by 0.91% to HKD 110.900, while its ADR price was HKD 110.069, down by 0.831 [3] - Other notable declines include Xiaomi Group (01810) down 2.09% to HKD 53.850 and JD.com (09618) down 2.14% to HKD 137.200 [3]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 請參閱百濟神州有限公司（「百濟神州」或「本公司」）於2023年6月16日和2025年4 月30日就Pharmacyclics LLC（「Pharmacyclics」）發起的專利侵權指控發佈的公告。 本公司宣佈，Pharmacyclics決定不對美國專利商標局的最終書面決定提起上 訴，該最終書面決定宣布Pharmacyclics在專利授權後複審程序中受到百濟神 州質疑的第11,672,803號美國專利（「'803專利」）的全部權利無效。百濟神州和 Pharmacyclics於2025年9月30日（美國時間）向相關地方法院提交一份共同協議， 自願撤回訴訟案件，案件已做出終局處理。 承董事會命 百濟神州有限公司 主席 歐雷強先生 香港，2025年10月2日 BeOne Medicines Ltd. 百濟神州有限公司 （根據瑞士法律註冊成立的公司） （股份代號：06160） 於本公告日期，本公司董事會包括主席兼執 ...